02.28.25 -- For Gilead, Sustainability Is More Than A PR Effort

Dual sourcing strengthens the pharmaceutical supply chain for single-use assemblies. Learn how this strategy and multi-sourcing can enhance resilience and adaptability in the face of disruptions.

While barrier films in bags can be useful for cold chain applications, they do not fully protect against gas ingress and ignore other sources of permeability.

Cell banking stands at the forefront of medical advancement. This guide delves into the steps involved in protecting these priceless resources, from cell collection and processing to storage and cell expansion.

Your supply chain is only as strong as its weakest link. 52% of organizations attribute recalls to supplier-related issues, and proactive supplier quality management is essential to protect your brand.

Learn how to select high-quality raw materials for cell-based manufacturing in this exploration of the criticality of raw materials, from preclinical development to commercialization. 

Learn about protein aggregation mechanisms, the role of excipients in stabilization, and novel surfactants that prevent aggregation in therapeutic protein formulations in this webinar.

This study compares the impact of a specific Human Growth Factor Concentrate (hGFC) and fetal bovine serum (FBS) on the growth, expansion, and viability of MSCs.

Learn about best practices and strategies to optimize bioconjugate drug product tech transfers and supplies in clinical or commercial phase, and explore real-world case studies.

In this Q&A, KBI Biopharma process development experts discuss how advanced cell line development and transposase technology streamline the path to toxicology and first-in-human studies.

Poloxamer 188 stabilizes proteins in liquid formulations and protects cells from shear stress. Molecular weight and hydrophobicity variations influence its effectiveness in different biopharmaceutical applications.

Establishing an organization that can manage a diverse development pipeline for oncology therapies requires an equally diverse wealth of expertise.

As the landscape of CAR T-cell therapies evolves, these treatments are becoming more precise in targeting cancer cells and overcoming production challenges, and are poised to revolutionize oncology.

Learn about the process conditions and protocols that were chosen as optimization targets and the resulting improvements to ADC production and purification that assessing these parameters provided.

Experience the benefits of faster, more effective CAR-T cell production with this innovative three-day short-cycle process, designed to enhance patient treatment outcomes while reducing costs.

When it comes to bispecific antibody (BsAb) manufacturing, a well-optimized culture environment is essential for achieving high and consistent BsAb yields with the desired critical quality attributes.

Reduced the risk of contamination caused by repeated handling of the culture during transient protein production in suspension CHO cells.

Explore more detail on how to achieve a 2000L scale-up and studies that have been optimized through process characterization and experimental approaches to better understand key process steps.

Glycosylation, a prevalent modification of mAbs, significantly impacts their function. Delve into various techniques for analyzing released glycans and their relative efficacy in HILIC-FLR-MS.

How can you leverage flow electroporation technology to drive your biologics development forward and deliver gram-scale transient protein production within two weeks?

Learn to identify potential product failure points and design robust formulations and processes for lyophilized products backed by solid data.

Stringent QC release testing throughout biologic production, as mandated by health authorities, ensures product safety and quality through evaluations of identity, purity, potency, and critical quality attributes.

By leveraging transposase-mediated technologies together with transposon design to achieve semi-targeted integration, drug developers can more efficient and consistent biotherapeutic protein production.

AAV has become an increasingly popular vector for gene therapy applications, yet ongoing challenges related to process and analytical development often require significant expertise to navigate.